Update on 26 April 2021

This is a reminder that recruitment into the SUMMIT Study ends soon. In February an end date of 30 April was advised. This has been extended to 14 May to accommodate outstanding appointments. There are now over 12,800 participants in the study who will remain part of the research until 2023, unless they wish to withdraw. Since announcing the end of recruitment, the SUMMIT team has worked hard to bring people into the study whose recruitment was paused due to the COVID-19 pandemic. There will be no further attempts to contact potential participants after the end date.

For queries email uclh.hcpsummitstudy@nhs.net

---

Overview

UCLH is carrying out the SUMMIT Study to detect lung cancer early using low-dose CT (LDCT) screening of at-risk individuals and to support development of a new blood test for early detection of multiple cancer types. 

The SUMMIT Study, which began in spring 2019, has two aims: to detect lung cancer early using the proven method of low-dose CT (LDCT) screening of at-risk individuals; and to support development of a new blood test for early detection of multiple cancer types, including lung cancer. In addition, the study will provide evidence to inform a potential future national lung cancer screening programme. The study has so far recruited over 12,000 people aged 55-77 with a smoking history from north and east London. 

 

If you have any questions, contact the study team
e: uclh.HCPsummitstudy@nhs.net.

Find out more information on the SUMMIT Study.